myelodysplastic syndromes (MDS) | Page 6 | Aplastic Anemia and MDS International Foundation

myelodysplastic syndromes (MDS)

Orlando

Thank you for attending the 2017 Patient and Family Conference in Orlando, FL.

Thank you for attending the 2017 Patient and Family Conference in Orlando, FL.
Event Date: 
Sat, 11/04/2017 -
8:00am to 3:30pm
Conference Event Type: 

Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-β superfamily inhibitors

Author(s): 
Mies A, Platzbecker U
Primary Author: 
Mies A
Journal Title: 
Semin Hematol
Original Publication Date: 
Jul 2017

Patients with lower-risk

Bone Marrow Diseases: 

Optimizing the use of hypomethylating agents in myelodysplastic syndromes: Selecting the candidate, predicting the response, and enhancing the activity

Author(s): 
Madanat Y, Sekeres MA
Primary Author: 
Madanat Y
Journal Title: 
Semin Hematol
Original Publication Date: 
Jun 2017

Bone Marrow Diseases: 

Pro-inflammatory proteins S100A9 and TNFα suppress erythropoietin elaboration in myelodysplastic syndromes

Author(s): 
Cluzeau T, McGraw KL, Irvine B, Masala E, Ades L, Basiorka AA, Maciejewski JP, Auberger P, Wei S, Fenaux P, Santini V, List A
Primary Author: 
Cluzeau T
Journal Title: 
Haematologica
Original Publication Date: 
Oct 2017

Accumulating evidence implicates innate immune activation in the pathobiology of

Bone Marrow Diseases: 

Confronting Challenges in Finding Matches for Multiracial Patients

Person's Name: 
Krissy Kobata

34-year-old Krissy Kobata is a passionate patient and advocate/activist. Diagnosed in 2008 with MDS, she’s the epitome of resilience as she has waited for years to find a matched donor. She has devoted this time to helping other patients by enlarging the Be The Match® bone marrow registry.

Bone Marrow Diseases: 

Kansas City

Thank you for attending the 2017 Patient and Family Conference in Kansas City, MO.

Thank you for attending the 2017 Patient and Family Conference in Kansas City, MO.
Event Date: 
Sat, 10/14/2017 -
7:30am to 1:30pm
Conference Event Type: 

Haploidentical transplant in patients with myelodysplastic syndrome

Author(s): 
Marie Robin, Raphael Porcher, Fabio Ciceri, Maria Teresa van Lint, Stella Santarone, Gerhard Ehninger, Didier Blaise, Zafer Güllbas, Soledad Gonzáles Muñiz, Mauricette Michallet, Andrea Velardi, Linda Koster, Johan Maertens, Jorge Sierra
Primary Author: 
Marie Robin
Journal Title: 
Blood Advances
Original Publication Date: 
Jul 2017

The only curative treatment in patients with intermediate or high-risk myelodysplastic syndrome (MDS) is allogeneic hematopoietic stem cell transplantation (HSCT), which usually results in a long-term, disease-free survival rate of between 30% and 50%, depending on the disease risk and the type of donor. In patients without an HLA-matched sibling donor, a family haploidentical donor is an alternative option.

Bone Marrow Diseases: